---
title: "Taltz (ixekizumab) in plaque psoriasis: Specific populations questions"
description: "Specific populations questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: Is Taltz approved for children with plaque psoriasis? What are Taltz side effects in children with plaque psoriasis? Is Taltz safe and effective for adults 65 and older? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Specific populations questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Specific populations questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications: Specific populations](https://www.evicenter.com/medical-information/taltz/specific-populations).

## Pediatric use

<a id="taltz-pediatric-approval"></a>

### Is Taltz approved for children with plaque psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age

> “The safety and effectiveness of TALTZ have been established in pediatric subjects aged 6 years to less than 18 years with moderate-to-severe plaque psoriasis. The safety and effectiveness of TALTZ in other pediatric indications and for pediatric subjects less than 6 years of age have not been established.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=The%20safety%20and%20effectiveness%20of,age%20have%20not%20been%20established.)

<a id="taltz-pediatric-side-effects"></a>

### What are Taltz side effects in children with plaque psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age

> “TALTZ was evaluated in a placebo-controlled trial in pediatric subjects with moderate-to-severe psoriasis 6 to less than 18 years of age. A total of 171 subjects were studied (115 subjects on TALTZ and 56 subjects on placebo). Overall, the safety profile observed in pediatric subjects with plaque psoriasis treated with TALTZ every 4 weeks is consistent with the safety profile in adult subjects with plaque psoriasis with the exception of the frequencies of conjunctivitis (2.6%), influenza (1.7%), and urticaria (1.7%).”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=TALTZ%20was%20evaluated%20in%20a,influenza%20%281.7%25%29%2C%20and%20urticaria%20%281.7%25%29.)

> “In this clinical trial, Crohn's disease occurred at a greater frequency in the TALTZ group (0.9%) than the placebo group (0%) during the 12-week, placebo-controlled period. Crohn's disease occurred in a total of 4 TALTZ treated subjects (2.0%) in the clinical trial [see Warnings and Precautions (5.5)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20this%20clinical%20trial%2C%20Crohn%27s,%5Bsee%20Warnings%20and%20Precautions%20%285.5%29%5D.)

> “IXORA-PEDS: Adverse events during double-blind treatment period through week 12”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=IXORA%2DPEDS%3A%20Adverse%20events%20during%20double%2Dblind%20treatment%20period%20through%20week%2012)

> “Adverse Reaction
>
> Taltz (n=115) n (%)
>
> Placebo (n=56) n (%)
>
> Infections	37 (32%)	14 (25%)
> Injection site reactions*	14 (12%)	1 (2%)
> Allergic reactions/hypersensitivities	6 (5%)	1 (2%)
> Non-anaphylaxis	6 (5%)	1 (2%)
> Potential anaphylaxis	0	0
> Crohn's disease	1 (0.9%)	0
> Ulcerative colitis	0	0”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=Adverse%20Reaction,0)

> “<sup>*</sup>The most frequent injection site reactions were erythema and pain. All injection site reactions were mild to moderate in severity and did not lead to discontinuation of Taltz.”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=most%20frequent%20injection%20site%20reactions,lead%20to%20discontinuation%20of%20Taltz.)

> “List is not all-inclusive.”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=List%20is%20not%20all%2Dinclusive.)

## Specific populations

<a id="taltz-older-adults"></a>

### Is Taltz safe and effective for adults 65 and older?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Of the 4204 adult psoriasis subjects exposed to TALTZ, a total of 301 were 65 years or older, and 36 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects [see Clinical Pharmacology (12.3)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Of%20the%204204%20adult%20psoriasis,subjects%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “Population pharmacokinetic analysis indicated that age did not significantly influence the clearance of ixekizumab in adult subjects with plaque psoriasis. Subjects who are 65 years or older had a similar ixekizumab clearance as compared to subjects less than 65 years old.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Population%20pharmacokinetic%20analysis%20indicated%20that,less%20than%2065%20years%20old.)

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines)
